NasdaqGS:GHHealthcare
Guardant Health (GH) Is Up 19.8% After Raising Guidance on Strong Oncology Demand and Biopharma Deals
Guardant Health recently reported second quarter results showing strong demand across its core oncology and screening businesses, with management raising full-year revenue guidance on the back of rapid product adoption and expanding biopharma partnerships.
An interesting insight is that despite ongoing operating losses and continued reinvestment, the revised outlook reflected management's confidence in sustained growth, coinciding with positive sector sentiment following speculation of lower...